Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVUTOMETINIB and Cetuximab in Advanced KRAS Mutated Colorectal Cancer
NCT05200442Phase 2Suspended
- Sponsor
- University of Chicago
- Start
- Aug 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avutometinib in colorectal cancer (CRC), sponsored by University of Chicago. Started Aug 2022; status: suspended.
02
Drugs
avutometinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05200442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200442.